|
News
Nebu~flow selected for Innovate UK Scaleup Programme

GLASGOW, SCOTLAND, 25 JUNE 2026:
Nebu-Flow, an advanced aerosol drug-delivery company, has been selected as an Innovate UK Scaleup Programme company, joining a highly competitive national programme supporting innovation-driven businesses on their journey to international growth.
The designation places Nebu-Flow among a select group of high-potential ventures receiving strategic, director-level support to accelerate technical, regulatory and commercial scale-up. The programme provides access to a specialist Scaleup Board and experienced Scaleup Directors who operate together as a virtual executive team, helping companies take decisive steps toward investment readiness and global expansion
As part of the programme, Nebu-Flow will work closely with Innovate UK’s scale-up team to strengthen two core value drivers for investors. ISO 13485 readiness, including structured pre-audit preparation to support future medical-device regulatory submissions and a global IP roadmap, protecting Nebu-Flow’s growing portfolio of inhalation and aerosol-engineering technologies
This support will help Nebu-Flow refine its operational systems, strengthen quality and regulatory foundations, and sharpen commercial positioning as it prepares for its next phase of growth. This includes aligning its quality management system with medical-device requirements, securing IP assets across priority markets, and ensuring the platform is fully investor-ready.
Nebu-Flow’s selection builds on recent Innovate UK-funded progress, including development of a disruptive acoustic nebulisation technology that significantly expands the range of fragile and complex therapies that can be aerosolised, from small antisense oligonucleotides to large molecules such as plasmid DNA, without the damage associated with conventional jet or mesh nebulisers. The innovation also enables a wider range of liquid volumes, opening the door to future multi-dose devices and applications beyond respiratory disease.
Andrea Cusack, CEO of Nebu-Flow, said: “Becoming an Innovate UK Scaleup Programme company is a major accelerator for Nebu-Flow. The programme gives us access to exceptional expertise across regulation, IP, operations and commercial strategy, support that directly strengthens our path to market and enhances our value to partners and investors. It positions us to scale with confidence and speed.”
The designation comes at a pivotal moment for Nebu-Flow as it advances its next-generation inhalation platform toward clinical readiness and expands industry partnerships. With tailored support and access to a specialist scale-up board, the company aims to accelerate regulatory milestones, strategic collaborations and global market entry.
Nebu-Flow continues to grow its team in Scotland while building international partnerships focused on transforming the delivery of complex and fragile medicines to the lung.
About Nebu~Flow
Founded in Glasgow, Nebu~Flow brings together engineers, scientists and industry experts with deep experience in respiratory drug delivery. The company has secured more than £4.7 million seed investment to date and has received multiple industry accolades, including the CPHI Pharma Start-Up Initiative Award (2024). Nebu~Flow plans to continue growing its team in Scotland while building international partnerships to bring this technology to market globally.
For further information
Nebuflow@transatlanticent.com
